Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

BT20_24hr_DMSOvERLOTINIB_RNAseq and WHOLE GENOME CRISPR screen

ABSTRACT: BT20_24hr_DMSOvERLOTINIB_RNAseq and WHOLE GENOME CRISPR screen

PROVIDER: PRJNA623198 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR11484034.fastq.gz	Fastqsanger.gz
	SRR11484035.fastq.gz	Fastqsanger.gz
	SRR11484036.fastq.gz	Fastqsanger.gz
	SRR11484037.fastq.gz	Fastqsanger.gz
	SRR11484038.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 13

Similar Datasets

CRISPR-Cas9 RBM10 synthetic lethality screen

Project description:Genome-wide CRISPR-Cas9 knockout screen using TKOv1 sgRNA library was performed in isogenic RBM10-proficient and RBM10-deficient HCC827 cells.

2023-03-04 | E-MTAB-12724 | biostudies-arrayexpress

Genome-wide CRISPR-Cas9 screen in isogenic parental and RBM10-KO HCC827 cells

Project description:Genome-wide CRISPR-Cas9 knockout screen using TKOv1 sgRNA library performed in isogenic RBM10-proficient and RBM10-deficient HCC827 cells.

2024-03-01 | E-MTAB-13626 | biostudies-arrayexpress

CRISPR screen

Project description:CRISPR screen

2023-04-25 | OEX00023089 | NODE

CRISPR-screen

Project description:CRISPR screen

2025-03-27 | OEX00031362 | NODE

CRISPR-screen

Project description:CRISPR screen

2025-05-29 | OEX00031508 | NODE

BT20_24hr_DMSOvERLOTINIB_RNAseq and WHOLE GENOME CRISPR screen

Project description:BT20 (TNBC) cells were cultured with either DMSO (v/v%) or Erlotinib (10uM) for 24 hours to observe differential expression changes between conditions. CAS-9 expressing BT20 (TNBC) cells were transduced with a whole-genome library of CRISPR sgRNAs; then, cultured them with either DMSO (v/v%) or Erlotinib (10uM) and collected samples to observe differential sgRNA abundances between conditions.

2020-11-01 | GSE148096 | GEO

CRISPR screen to identify regulators of neuronal differentiation

Project description:To search for factors regulating neuronal differentiation, we performed a genome-wide loss-of-function CRISPR/Cas9 screen in haploid human ESCs. The regulators were identified by the quantification of depletion of their mutant clones within a pooled loss-of-function library upon neuronal differentiation.

2024-01-12 | E-MTAB-11944 | biostudies-arrayexpress

Whole-genome CRISPR screen to identify regulators of cold-shock protein RBM3

Project description:Whole-genome CRISPR screen to identify regulators of cold-shock protein RBM3

| PRJNA900543 | ENA

Whole-genome CRISPR screening identifies N-glycosylation as an essential pathway and a potential novel therapeutic target in CALR-mutant MPN (Whole Genome CRISPR Screen).

Project description:Calreticulin (CALR) mutations are frequent, disease-initiating events in myeloproliferative neoplasms (MPN). Although the biological mechanism by which CALR mutations cause MPN has been elucidated, there currently are no clonally selective therapies for CALR-mutant MPN. To identify unique genetic dependencies in CALR-mutant MPN, we performed a whole-genome CRISPR knockout depletion screen in mutant CALR-transformed hematopoietic cells. We found that genes in the N-glycosylation pathway (amongst others) were differentially depleted in mutant CALR-transformed cells as compared with control cells. Using a focused pharmacological screen targeting unique vulnerabilities uncovered in the CRISPR screen, we found that chemical inhibition of N-glycosylation impaired the growth of mutant CALR-transformed cells in vitro. We treated Calr-mutant knockin mice with the N-glycosylation inhibitor, 2-deoxy-glucose (2-DG), and found a preferential sensitivity of Calr-mutant cells to 2-DG as compared to wild-type cells, and a normalization of key MPN disease features. These findings advance the development of clonally selective treatments for CALR-mutant MPN.

2022-09-21 | GSE203456 | GEO

Genome-wide CRISPR KO screen in BMDMs [Bulk CIRSPR Screen]

Project description:Genome-wide CRISPR KO screen in BMDMs [Bulk CIRSPR Screen]

| PRJNA865297 | ENA